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ABSTRACT

Mercer, Elizabeth. M.S.B.M.E., Purdue University, December 2014. Synthesis of
Multilayered Microparticles for Targeted Drug Delivery. Major Professor: Alyssa
Panitch.
Microparticles have been shown to be valuable in targeted drug delivery which can
lead to an increased dose delivered to a targeted location, reduced patient side effects, and
improved patient outcomes. The designed multilayered microparticles have the clinical
application to deliver hydrophobic drugs to a targeted area. The composition of the
microparticles consists of a poly-lactic acid (PLA) polymer core surrounded by a polymeric
shell composed of Poly(lactic-co-glycolic acid)-Poly(ethylene glycol)-Maleimide(PLGAPEG-Mal). The maleimide promotes conjugation of the collagen binding peptide, SILY.
Targeting to type I collagen allows for this microparticle system to attach to exposed collagen
in atherosclerotic vessels.
A novel templating method was used to synthesize uniform microparticles with
manufacturing scale-up potential. Modification of the templating method was necessary to
synthesize hydrophilic, multi-layered microparticles. The experimental results verified and
quantified the presence of attached fluorescent SILY to the maleimides present on the surface
of the microparticles as well as the microparticles' attachment to type I collagen. These
results signify that the designed microparticles have the potential to deliver hydrophobic
drugs to type I collagen throughout the body and potentially target atherosclerotic regions.
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CHAPTER 1. INTRODUCTION

1.1

Drug Delivery Systems

Drug delivery systems advancements have led to the treatment of a variety of
diseases. Drug delivery systems are defined as “engineering technologies for the targeted
delivery and/or controlled release of therapeutic agents” [1]. Nanoparticles and
microparticles are growing as a major component of novel drug delivery processes. Nano and
microparticles have been shown to be valuable in the following:


targeted drug delivery to diseased tissues



decreased dose delivered systemically and potential tissue damage [2]



increased dose delivered locally to diseased tissues



reduced side effects in sensitive, non-target tissues [2]



controlled drug release [3]



improved patient outcomes

Ultimately, nano and microparticles have the potential to provide improved therapy and
diagnostics to more patients.
Due to the increased amount of research performed on nano systems, it is important
to understand the distinction between nano and microparticles. Nano and microparticles are
so referred based on the distinction between dimensions in terms of nanometer and
micrometers respectively; these size differences can have numerous effects on the mode and
type of therapy delivered[4]. The benefits of larger particles are as follows:
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they are less likely to aggregate and potentially cause occlusions [4]



they have the potential for higher drug loading



they have a longer time for degradation

Microparticles have a tendency to remain localized in diseased tissue after direct
injection [4]. For example, microparticles with 5-250 µm diameter remained in the
peritoneum of mice for at least two weeks compared to the same mass of nanoparticles which
were cleared from the peritoneum in two days [4, 5]. Microparticles are the chosen drug
delivery systems in order to provide increased long-term treatment to diseased areas.
Similar to any system, microparticles have their limitations. Smaller particles have
better binding affinity compared to larger particles [4]. The binding affinity can be combated
by adding a targeting ligand, such as a peptide, to the outside of the microparticle to increase
binding to particular cells. Also, larger microparticles have the potential to cause
embolization within blood vessels. They may lodge in the pulmonary vasculature causing a
pulmonary embolism or may lodge in end organs causing ischemia and possibly necrosis.
The exact particle size to prevent this is unknown, but large quantities of 4-5µm particles
were injected into the carotid arties of mice without causing detectable problems [4, 6].
Based on previous research, 5µm is the upper limit for target microparticle size to prevent
embolization potential. Due to the numerous benefits of microparticles as well as the methods
to combats their limitation, microparticles are the chosen drug delivery system.

1.2

Microparticle Design

Microparticles can be adaptable with the delivery of different drugs to various
locations within the body based on their unique design. The overall design of the
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microparticles in this study consisted of a hydrophobic polymer core surrounded by a
hydrophilic polymer shell with attached targeting peptides shown here in Figure 1.1.

Figure 1.1 Depiction of the overall designed microparticle system. The blue and orange
regions represent the hydrophobic core surrounded by the green hydrophilic shell. The
polymer shell also contains a reactive group which allows for the attachment of the
targeting peptide.
This amphiphilic system provides many advantages to this drug delivery system by
having the potential to incorporate a hydrophobic drug within the hydrophobic polymer core.
Hydrophobic drugs tend to have poor solubility in the body’s aqueous environment [2]. The
amphiphilic system enhances drug solubility by providing both a hydrophilic environment for
the body to interact with and a hydrophobic environment to encapsulate the drug [2].

1.2.1 Hydrophobic Polymer Core
The hydrophobic polymer core is composed of poly-lactic acid (PLA). PLA is
commonly used for controlled drug delivery because it is a well-known, biodegradable,

non-toxic polymer [7,8]. PLA was chosen as the core material due to its hydrophobic
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properties, which inhibited diffusion into the hydrophilic PVA template and provided the
structural integrity for the microparticles.
The hydrophobic effect of the PLA core promotes interaction with the hydrophobic
region of the polymer shell. Poly(lactic-co-glycolic acid)- Poly(ethylene glycol)- Maleimide
(PLGA-PEG-Mal) composes the polymer shell, however the hydrophobic PLGA
incorporates into the core with which it is miscible. PLGA provides many benefits in medical
systems due to its biodegradability, biocompatibility, predictability of degradation, ease of
fabrication, and FDA approval [9, 10].

1.2.2

Hydrophilic Polymer Shell

Polymer shell coatings provide many advantages to drug delivery systems. A
significant advantage is that these shells provide drug diffusion control which slows the
release of drug from the core of the microparticle [3]. The polymer used to form the shell is
Poly(lactic-co-glycolic acid)-Poly(ethylene glycol)–Maleimide (PLGA-PEG-Mal). While the
PLGA intercalates into the core to hold the shell in place, the PEG remains largely within
PEG-rich layer at the particle surface. Significant research has been performed on the use of
PLGA and PEG in drug delivery systems. These polymers are both biodegradable and their
rate of degradation is linked to the chain length [11]. PLGA-PEG microparticles have been
synthesized to deliver pulmonary drugs [12], anti-inflammatory drugs [13], and

neurotrophic factor used to treat Parkinson’s Disease [14]. Based on the numerous benefits
of PLGA and PEG, these polymers are ideal for use as a polymeric shell for this
microparticle system.
Since the hydrophobic PLGA incorporated into the core, the hydrophilic PEG is the
main component of the shell. The PEG facilitates the aqueous-based conjugations and
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inhibits particle aggregation within the body [15]. PEG coatings have been found to be nonimmunogenic, so they provide protection against interaction with the blood components,
which induce the removal of the foreign particles from the blood [16, 11]. Therefore, the
circulation time of microparticles with PEG ensures that the microparticles have sufficient
time to target and deliver therapy to the diseased areas within the blood vessels.
The PEG has a terminal maleimide functional group allowing for attachment of
targeting peptides containing a sulfhydryl or amine. The PEG is highly flexible which allows
for peptide conjugation to the maliemide without significant steric hindrance of the peptide
ensuring that it is available to bind to its target [16]. For reaction mixtures with a pH greater
than 8.5, the maleimide favors a reaction with a primary amine, but also the alkaline pH
increases the rate of hydrolysis to a non-reactive maleamic acid [17]. For reaction mixtures
with a pH between 6.5 and 7.5, the maleimide reacts with a sulfhydral to form a stable,
nonreversible thioether linkage [17]. All experiments were executed at a pH of 7.4 to enhance
maleimide reaction with sulfhydryl groups. Buffers or agents with free sulfhydryls or free
amines should not be used in the synthesis of these microparticles as they have the potential
to react with the free maleimides. This overall microparticle design has the potential to be
used to deliver various hydrophobic drugs to various targeted tissues within the body based
on the chosen targeting peptide.
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1.3
1.3.1

Microparticle Application
Atherosclerosis Background

Atherosclerosis is most commonly characterized by the accumulation of lipids and
fibrous elements in the large arteries; however, it is now recognized as a chronic
inflammatory disease. [18, 19]. Atherosclerosis has the clinical implication of a build-up
of plaque along artery walls which potentially leads to heart attack, stroke, or even death
[18, 20]. Collagen Type I is a major component of deep vessel injury on an
atherosclerotic vessel injury present after balloon angioplasty or plaque rupture [21]. The
target diseased area for these particular microparticles is atherosclerotic tissue along vessel
walls.

1.3.2

Collagen Binding Peptide

Collagen is the most abundant protein in animals [23]. It is located in and maintains
the integrity of the extracellular matrix and connective tissue [23, 24]. Due to the
mechanical resilience of collagen, it has become highly used for different biomedical
applications including: biomimetic cell culture scaffold and tissue engineering [25, 26].
There are at least twenty-nine types of collagen, but types I, II, and III are the most
abundant [27]. The building block of collagen is tropocollagen which is composed of
three helical polypeptide chains that containing the triplet Gly-X-Y [27, 23]. Type I
collagen has many benefits including its ability to self-assemble in vitro, resilient
mechanical properties, and hierarchical structure [26]. The microparticles will be tested
to see if attachment occurs with type I collagen from rat tail [28]. Rat tail tendon-rich
tissue makes fibrous type I collagen easy to isolate and readily available [24]. The
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fundamental collagen unit of rat tail type I collagen is a long, thin protein that consists of
three coiled subunits [24]. Due to the abundance of collagen in the body, there are many
diseases associated with collagen that would benefit from a drug delivery system
targeting collagen. For this reason, a collagen binding peptide was then attached to the
polymer shell to promote collagen type I attachment.

In order to effectively target type I collagen, a collagen binding peptide can be
attached to the shell of the microparticles. Various synthetic peptidoglycans that bind to
type I collagen have been or are currently being synthesized in the Panitch laboratory
[29-31]. During development of the peptidoglycans, the peptide sequence
RRANAALKAGELYKSILYGC (SILY) was shown to bind with Collagen Type I on its
own or when bound to hydrophilic polymers [31]. SILY was derived from the platelet
receptor to collagen type I and was modified to use a cysteine sulfhydryl group for
conjugation to polymers [31]. The sulfhydryl group at the C-terminus of SILY allows for
conjugation to the maleimides available on the shell of the microparticles. For this
reason, SILY was the chosen collagen-binding peptide for this system.

Figure 1.2 Depiction of the overall microparticle system including the collagen binding
peptide, SILY described below.
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1.4

Microparticle Synthesis Method

1.4.1

Common Synthesis Methods

To date, microparticles have been prepared by emulsion-solvent evaporation, phase
separation, interfacial polymerization, spray drying, emulsion extraction process, jet milling
technique, and fluidization [10]. The common emulsion methods result in particles with
different size distributions [32]. The uniformity of the size of the particles has a significant
influence on the drug release rates. Particle size can be controlled by various factors for the
conventional synthesis methods including: varying polymer concentration [33] and choice of
polymer chemistry [34]. Various studies have found difficulties in producing uniformly sized
particles for drug release studies [33, 35]. However, some researchers have shown that larger
particles release encapsulated compounds more slowly and over an extended time period with
the other properties (molecular weight, initial porosity, drug distribution with the sphere)
being equal [34]. Drug release studies have shown that the initial drug release rates decreased
with increasing particle diameter due to the decrease in surface/volume ratio with increasing
size [34]. This resulted in a concave downward and sigmoidal release profile curve for small
and large particles respectively [34]. Thus, the uniformity of microparticles is essential to
understanding and controling drug release rate profiles. Fortunately, a templating method
developed by Dr. Kinam Park’s lab at Purdue University has shown promise in producing
uniformly sized particles among other benefits.

1.4.2

Park Templating Method

The particle size can be easily controlled using the Park templating method just with
the use of different template sizes ranging from 6-50µm [36]. The template used in these
studies made 50µm column height and diameter microparticles. The Park templating method
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also has the scale-up potential for manufacturing using the new automated microparticle
synthesizer, the SpinSwiper [36].
The Park templating method (shown in Figure 1.3) produces microparticles by using a
silicon master template. The silicon master template is then used to form a degradable
template made of gelatin or poly(vinyl alcohol) (PVA). The desired polymer solution is
poured into the gelatin or PVA template with the excess solution removed. The solvent in the
polymer solution evaporates, and the gelatin or PVA can be melted and removed leaving
column shaped particles. Since the shape of the particles has previously been limited to a
sphere, the Park templating method will allow research of different particle shapes on
biological responses. Another benefit of this synthesis method is that the gelatin mold
dissolved so the particles are released without mechanical methods.

Figure 1.3 Schematic of the Park Microparticle Synthesis Process [32]. A: The silicon master
template is made by photoliography. B: A warmed gelatin solution is cooled on the master
template. C: The master template is peeled away exposed open wells to make uniform
microparticles. D: The wells are filled with polymer solution and the excess solution is
removed with a razor blade. E: The gelatin is heated and removed with centrifugation. And,
the final product of the microparticles remains.

In order to adapt this procedure to synthesize the multilayered microparticles, the
PLGA-PEG-MAL and PLA are added in separate layers. The hypothesis with this procedure
was that the hydrophilic PEG would preferentially face or diffuse into the template surface.
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And, the hydrophobic PLGA would preferentially remained exposed to the air interface and
would be available to intercalate into the core of the particles when the PLA solution was
added to the template. The final PEG-PLGA layer to the template particle surface would
allow for complete coating of the PLA particles with a PEG shell. Adapting the Park
templating method for synthesizing multilayered microparticles could be used to treat a
variety of diseases in various locations of the body.
The overall goal of this research is to develop a novel microparticle drug delivery
system synthesized by adapting the Park templating method. Chapter 2 describes the adapted
synthesis method and the methods for analyzing the synthesized microparticles. Chapter 3
shows the obtained results of verifying surface maleimides and the collagen binding
capabilities of the microparticles. Chapter 4 describes the benefits of this microparticle
system as a novel platform for new drug delivery methods.
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CHAPTER 2. METHODS

2.1

PVA Template Synthesis

Poly(vinyl alcohol) (PVA) was purchased from Sigma-Aldrich. The 4% (w/v) PVA
was dissolved in 500mL of deionized water with constant stirring at 60˚C. After full
dissolving of the PVA, 500mL of ethanol was slowly added to the PVA solution with
constant stirring at 60˚C. The PVA solution was left at room temperature.

2.1.1

Preparation of PVA Templates

A Polydimethylsiloxane (PDMS) template with 50µm column height and width
wells was purchased from Akina, Inc (Cat # AKPDMS-50). The wells were formed with
photolithography. The PDMS template was placed on a glass slide with the wells facing
upright. Then, 8mL of PVA solution was pipetted onto the side of the PDMS template
containing the wells. The PVA solution was allowed to dry at room temperature
overnight on a flat surface. The dried PVA template was then peeled away from the
PDMS template exposing the formed wells. The templates were stored in a dry, covered
container until used. The PDMS molds were cleaned after approximately 30 pours with
warm, soapy water. The PDMS molds were allowed to dry before the next pour.
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2.2

Preparation of Polymer Solution

The acid terminated polymer, poly(DL-Lactide) (PLA), was purchased from
Lactel Absorbable Polymers (CAT #B6014-1). The PLA has an inherent viscosity
between 0.15-0.25kDa [1]. A 20% w/v solution of PLA in Dichloromethane (DCM) was
prepared in a glass vial. And the solution was mixed for 30 minutes. This PLA solution
was prepared to later form the core of the microparticles.
The Poly(lactide-co-glycolide)-b-poly(ethylene glycol)-maleimide (PLGA-PEGMal) was purchased from Akina, Inc. (Cat #AI20). The molecular weight of the PLGAPEG-Mal was 20:5 kDa. The PLGA-PEG-Mal was prepared as a 5% solution in DCM.
The polymer-solvent solution was mixed for 30 minutes. The PLGA-PEG-Mal was
prepared to later form the shell of the functionalizable microparticle
The Methoxy poly(ethylene glycol)-b-poly(lactide-co-glycolide) (mPEGPLGA) was purchased from Akina, Inc. (Cat #AK02). The molecular weight of the
mPEG-PLGA was 2:4.11 kDa. The mPEG-PLGA was prepared as a 5% solution in DCM
and was mixed for 30 minutes. The mPEG-PLGA was prepared to later be used as the
shell of the negative control microparticles.
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2.3

Microparticle Synthesis

The PVA templates were prepared for microparticle synthesis by cutting each PVA
template into approximately 4 strips without any bubbles in the template. The templates
were each placed onto an individual glass slide and taped on the top and bottom to
prevent shifting.

2.3.1

Functionalizable Microparticle Synthesis [2]

The functionalizable microparticles were composed of a PLA core with a PLGAPEG-Mal shell. These functionalizable microparticles were formed by pippetting 9µL of
PLGA-PEG-Mal/DCM onto one PVA strip. The polymer solution was then quickly
spread evenly around the PVA strip. This process was repeated for each strip. The
polymer solution was allowed to dry for 15 minutes.
The PLA solution was used to form the core of the microparticles on top of the
PLGA-PEG-Mal layer. After allowing the PLGA-PEG-Mal solvent to evaporate, 9µL of
20% PLA solution was pipetted onto one strip and spread evenly with a razor blade. This
step was repeated for each strip. The PLA solution was allowed to dry for 15 minutes.
Then, the final layer of the shell was applied by pippetting 9µL of the 5% PLGA-PEGMal solution onto a single PVA strip and spreading evenly with a razor blade. This was
repeated for each strip and then the polymer solution was allowed to dry for 15 minutes.
After the drying process, the strips were cut using a razor blade to remove them
from the glass slides. The strips were then placed into a 50mL beaker.
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2.3.2

Negative Control Microparticle Synthesis [2]

The negative control particles were synthesized with the same steps of the
functionalizable microparticles except in place of the PLGA-PEG-Mal, the mPEG-PLGA
was used because of the unreactive methyl group on the end.
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2.4

Attachment of Peptides

2.4.1 Attachment of FITC-SILY
The FITC-Ahx-RRANAALKAGELYKSILYGC (FITC-SILY) was purchased as
a custom order from GenScript. A 2mg/mL solution of FITC-SILY with 1x Phosphate
Buffered Saline (PBS) with a pH of 7.4 was prepared in the dark. This solution was
mixed for one hour. The FITC-SILY solution was placed on top of the strips in the 50 mL
beaker and was stirred for one hour at room temperature in the dark. This allowed the
PVA template to fully dissolve and the FITC-SILY to conjugate to the available
maleimide groups at the particle surface. The dissolved PVA and excess peptide were
removed by centrifuging the sample at 5,000rpm for 5 minutes and discarding the
supernatant. A wash using 1x PBS was repeated three times. The microparticles were
then viewed under a light microscope to view the integrity of the particles and lyophilized
overnight. The microparticles were stored at -20˚C. The attachment of FITC-SILY was
essential for the later validation of FITC-SILY on the surface of the microparticles and
for the quantification of FITC-SILY attachment.

2.4.2

Attachment of SILY

The RRANAALKAGELYKSILYGC (SILY) was purchased as a custom order
from GenScript. The same procedure was used for the attachment of SILY that was
described for the attachment of FITC-SILY except that the FITC-SILY was prepared at a
concentration of 0.0156mg/mL in 1x PBS.
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2.5
2.5.1

Validation Experiments

Validation of FITC –SILY Attachment to Microparticle Surface

The presence of attached FITC-SILY was validated using an FV1000/IX81
confocal microscope. Samples of the FITC-SILY-Mal-PEG-PLGA and the negative
control microparticles were placed onto glass slides. These slide were analyzed used the
488 laser of the confocal microscope for review.

2.5.2

Quantification of FITC-SILY Attachment to Microparticles

The procedure for the attachment of FITC-SILY for this experiment differed
slightly from the procedure described above because it was noted that there was some
FITC-SILY non-specific interactions and peptide clumping. The only differences to the
procedure described above are listed here. To prevent non-specific interaction of FITCSILY with negative control microparticles, a methyl-PEG-PLGA with a molecular
weight of 5,000:4,000 Da (Cat# AK30) was purchased from Akina Inc and used to form
the polymer shell of the negative control microparticles. To reduce the clumping, a
0.0156mg/mL solution of FITC-SILY in 1x Phosphate Buffered Saline (PBS) with a pH
of 7.4 was prepared in the dark with a small amount of Tris(2-carboxyethyl)phosphine
hydrochloride (TCEP-HCl) [3] (Thermo Scientific (Product# 20490)). This solution was
mixed for one hour. Then one wash was performed to remove any undissolved FITCSILY by centrifuging at 5,000rpm for 5 minutes. The FITC-SILY solution was placed on
top of the strips in the 50 mL beaker and was stirred for one hour at room temperature in
the dark. This allowed the PVA template to fully dissolve and the FITC-SILY to
conjugate to the available maleimide groups at the particle surface. The dissolved PVA
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and excess peptide were removed by centrifuging the sample at 5,000rpm for 5 minutes
and discarding the supernatant. A wash using 1x PBS was repeated three times. The
microparticles were then viewed under a light microscope to view the integrity of the
particles and lyophilized overnight.
The following day, 100µL of 1xPBS was placed into twelve wells of a black 96well plate with a clear bottom. 0.06mg of experimental and negative control
microparticles was measured and placed into individual wells in the dark. Six replicates
were analyzed for the experimental and negative control groups. The 96-well plate was
analyzed with a SPECTRAmax M5 Plate Reader with the following settings:


Endpoint reading



Fluorescence – bottom read



Excitation: 495nm



Emission: 519



Automix: Once for 5 seconds before first read



Calibrate: On



PMT: Medium



Settle Time: Off



Column Priority



C. Speed: Normal

The data was then analyzed based on the output from the M5.
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2.5.3

Validation of Microparticles’ Collagen Binding Capabilities

The ability for the SILY-Mal-PEG-PLGA microparticles to bind to collagen was
validated using a collagen-binding assay. Collagen I 96 clear well plates were purchased
from Fisher Scientific (Cat # 08-774-1). The collagen plate was blocked with 2% BSA to
prevent non-specific binding for one hour at 37˚C. The plate was washed three times with
1xPBS. The SILY-Mal-PEG-PLGA and negative control microparticles (Me-PEGPLGA) were separately suspended in 1x PBS at a pH of 7.4 at a concentration of
1.4mg/mL. Then, 100µL of microparticle solution was pipetted into each of 6 wells of the
collagen plate. The 96-well plate was covered and incubated for 30 minutes at 37˚C. The
wells were then washed three times with 1x PBS. The microparticles present in each well
were imaged with a light microscope and manually counted.
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CHAPTER 3. RESULTS

3.1

Validation of FITC –SILY Attachment to Microparticle Surface

The described protocol was developed after first performing the published Park
method to synthesize microparticles that are composed entirely of PLGA [3]. The results
from this preliminary data showed that particles had a tendency to agglomerate in the water
solvent most likely due to the hydrophobic nature of PLGA. This agglomeration made
imaging and the size analysis of individual particles difficult. This agglomeration was not
observed with the PLGA-PEG particles in water indicating a presence of PEG on surface that
forms hydrogen bonds with the water thus preventing agglomeration of the particles. The
dispersed particles can be seen clearly in Figure 3.1 shown below. The presence of the
hydrophilic PEG on the surface also provides the opportunity to attach peptides, via a
reactive PEG end group, to the particle surface to encourage particle binding to a target
molecule.

The Mal-PEG-PLGA microparticles shown in Figures 3.2 and 3.3 below validate
that the FITC-SILY is interacting with the surface of the particles. This interaction is
most probably a reaction between the maleimide on the microparticle and the free
cysteine in the SILY. Figures 3.2-3.3 show distinctive green fluorescent rings around a
non-florescent polymer core. This same lack of fluorescence was seen in the negative
control microparticles in Figure 3.4, suggesting that the peptide is able to conjugate to the
maleimide on the particles coated with the PLGA-PEG-maleimide.
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Figure 3.1 Light microscope images of the SILY-Mal-PEG-PLGA microparticles
shown on the left. The right image shows the negative control microparticles
composed of Me-PEG-PLGA.

Figure 3.2 Mal-PEG-PLGA microparticles reacted with FITC-SILY. Microparticles
were analyzed using a 488 laser on a confocal microscope. The microparticles are
shown here in an overlayed image with white and fluorescent light. The
microparticles shown in these two images represent microparticles in different
batches on different days. This experiment was run in triplicate to ensure consistency
of the results.
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Figure 3.3 Negative control microparticles visualized with the confocal microscope
with the 488 laser.
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3.2

Quantification of FITC-SILY Attachment to Microparticles
3.2.1

Standard Curve

Table 3.1: Standard Curve Data of FITC-SILY Concentration from SPECTRAmax M5.
FITC-SILY
Concentration
0.015625
0.0078125
0.00390625
0.001953125
0.000976563
0.000488281
0.000244141
0.00012207
6.10352E-05
3.05176E-05
1.52588E-05

Fluorescence
6638.9
2986.2
2071.6
767.98
924.43
164.89
107.81
92.616
91.295
58.673
60.723

FITC-SILY Standard Curve
7000
y = 413926x + 94.205

Florescence (RFUs)

6000
5000
4000
3000
2000
1000
0
0

0.002

0.004

0.006

0.008

0.01

0.012

0.014

0.016

0.018

FITC-SILY Concnetration (mg/mL)

Figure 3.4: FITC-SILY Standard Curve graph used to quantify FITC-SILY
attachment to microparticles.
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3.2.2

Results of Quantification of FITC-SILY Attachment to Microparticles

Table 3.2: Experimental results showing the concentration of FITC-SILY Attached
to experimental and negative control microparticles. Table Key: Exp= Experimental
Samples, NC= Negative Control Samples, Avg=Average.
Exp

Sa
mp
le
1 Exp

1

2

3

4

5

6 Avg

716

473

285

682

3034

293 913.7

NC

162

209

171

269

178

180 194.8

39.6

0.000189537

2 Exp

580

223

497

306

166

420 365.2

161.0

0.00053036

NC

133

106

109

205

96

95 124.0

42.1

4.79593E-05

3 Exp

474

126

324

264

231

88 251.2

139.8

0.0003024

NC

40

54

49

55

58

55.6

12.4

-0.000088736

4 Exp

285

146

192

271

169

90 192.1

74.9

0.000184282

NC

30

62

87

60

62

50.7

-4.05483E-05

77
177

79.7

Standar
d Dev

Concentration
of FITC-SILY
(mg/mL)
1054.8
0.00162737

The statistics were analyzed for the quantification experiment of FITC-SILY
attachment to micorparticles. A normality test was first performed on each data group
to determine normality. The normal data sets were analyzed using a two sample Ttest, while the non-normal data was analyzed using a Mann-Whitney test.

Table 3.3: Statistical analysis showing a statistical difference between the
experimental and negative control samples.
Experiment Statistical Test
1
2
3
4

Mann-Whitney
Mann-Whitney
2 sample t-test
Mann-Whitney

PAlpha Significantly
value
Different
0.0051
0.05 Yes
0.0082
0.05 Yes
0.016
0.05 Yes
0.0202
0.05 Yes
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Concentration of FITC-SILY (mg/mL)

Concentration of FITC-SILY on Experimental and
Negatvie Control Microparticles
0.0007
0.0006
0.0005
0.0004
0.0003

Experimental

0.0002

Negative Control

0.0001
0
-0.0001 0
-0.0002

1

2

3

4

5

Experiments

Figure 3.5: Graphical representation of the concentration of attached FITC-SILY to
the experimental microparticles compared to the negative control microparticles.
Figure 3.5 does not include data point from Experiment 1 Sample 5 from the
experimental microparticles because it is an outlier from this data. This outlier can be
attributed to excess undissolved FITC-SILY present in the sample.
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3.3

Results of Microparticles’ Collagen Binding Capabilities

The ability of the attachment of a targeting peptide may greatly facilitate the
application of the designed microparticles for drug delivery. SILY-Mal-PEG-PLGA
microparticles were found to be attached to the collagen type I bound plate by
counting whole microparticles attached to the collagen plate. Microparticle
particulates were excluded from the microparticle count.

Table 3.4: Results of the attached microparticles to the collagen type I plate.
Experiment Samples
1 Experimental
Negative
Control
2 Experimental
Negative
Control

1 2 3 4 5 6 Average St Dev
25 13 15 12 31 31
21.17
8.13
2 1 1 5 6 5
3.33
2.05
10
1

8
4

8 17
3 1

5
1

1
1

8.17
1.83

4.88
1.21

A statistical analysis was performed on the collagen binding capability data.
First, a normality test was run on all sets of data to determine if the data was normal.
A two sample T-test was performed for normal data, and a Mann-Whitney test was
performed for non-normal data.

Table 3.5: Statistical analysis of the attached microparticles to the type I collagen
plate.
Test
2 Sample Ttest
MannWhitney

PAlpha Significantly
value
Different
0.005
0.05 yes
0.0247

0.05 yes
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Figure 3.6: Bound experimental (SILY-Mal-PEG-PLGA) microparticles attached to
the collagen type I plate. This image was taken from experiment 1’s results.
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CHAPTER 4. DISCUSSION

4.1

Adapting the Park Templating Method
4.1.1

Order of Assembly

There are many unique aspects of the Park templating synthesis method including the
order of assembly. The designed microparticles are composed of an outer most layer of
collagen binding peptides attached to a polymer shell. The polymer shell is composed of
PLGA-PEG-Mal. The maleimides allow for the attachment of the collagen binding peptide.
The polymer shell forms as an integrated layer with the hydrophobic PLA in the core of the
microparticle and presents the hydrophilic PEG on the outside of the particle to form a
polymeric shell as shown in Figure 1.2. The hydrophobic drug can be encapsulated within the
polymeric shell. The order of assembly for these microparticles is different from the tradition
reverse order of assembly for many nanomedical systems. Many systems are manufactured
from the core to the outermost shell in the reverse order that the layers are actually used
within the body. Due to the templating method used, the order of synthesis is a layer of the
polymeric shell followed by a layer of the hydrophobic drug then a final layer of the
polymeric shell. The assembly ends with the addition of the collagen binding peptide.

4.1.2

PVA as a Template

As described in the introduction, gelatin was the suggested template to use during
synthesis of the microparticles [1]. Gelatin was used for the initial experiments of
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microparticle synthesis, however no fluorescence was seen after attempting to conjugate
thiol-terminated fluorescent peptide to surface maleimide groups on the template.
This suggested that functionalizable maleimides were not present on the surface of the
microparticles. It was hypothesized that the maleimide was reacting with the gelatin,
since gelatin contains lysine which contains a free amine group [2]. During the time of
solvent evaporation or when the gelatin was being dissolved away from the formed
particles, it is possible that the maleimides were reacting with the lysine in the gelatin.
PVA has been used to synthesis particles in other studies and does not contain groups that
are reactive with maleimide. For this reason, PVA template was chosen to prevent the
unwanted maleimide reaction with the template. Microparticles synthesized using a PVA
template allowed for successful attachment of FITC-SILY to the maleimide on the
surface of the microparticles

4.1.3

Multilayered Potential

The three layers of polymers that compose these microparticles allow for a unique
drug delivery system. The unique layers of the microparticle allow for different functions
to be present within one delivery system. The hydrophilic shell prevents agglomeration of
the microparticles and enhances the interaction with the body’s aqueous environment.
The hydrophobic polymer core allows for the incorporation of hydrophobic drugs in
future experiments. The designed procedure can be modified to include more layers
through decreasing the polymer concentrations. The potential for adapting this procedure
is limitless and can include layers to enhance imaging of the microparticles, pH
specificity, or multiple drug layers.
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4.1.4

Incorporating Hydrophilic Polymers

Previous experiments using the Park templating method used the hydrophobic
polymer PLGA and/or PLGA-drug combinations for microparticle synthesis [1, 3]. So,
the Park templating method needed to be adapted for synthesizing microparticles with a
hydrophilic PEG shell. PLGA with drug combinations was shown to maintain its
structure as a cylinder or as alphabet letters and was found not to diffuse into the template
[1]. Diffusion into the hydrophilic template was prevented because a hydrophobic
nonpolar solution was used. A solely hydrophilic solution would be miscible with the
template and diffuse into the template. So, the PLGA-PEG-Mal provides the hydrophobic
PLGA and the hydrophilic PEG that when the solvent is slowly evaporated from the
polymer solution, the PEG interacts with the PVA and the PLGA is exposed to the air
thus forming a core shell in the process. Overall, the hydrophilic shell will prevent
aggregation in the body and specifically in the blood system.

4.1.5

Comparison to Other Hydrogel Synthesis Procedures

The Park templating method varies greatly from other methods of microparticle
synthesis such as oil immersion techniques. However, the molding technique for
microparticle synthesis represents a similar synthesis method. For the molding technique
by Yung and Li, a polymer is poured into a mold of any shape and size. A gelling agent
or temperature change causes the polymer microparticle to gel, and the microparticles can
be removed from the mold [4]. This molding techniques has similar benefits to the
templating method in that uniform particles form, procedure is simple and inexpensive,
and there is a potential for scalable fabrication [5]. Yung and Li successfully attached a
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reactive fluorescein to the microparticles using chitosan’s abundant amine groups
showing the microparticles’ targeting ligand conjugation potential [5]. This molding
technique shows an example of functionalizable microparticle composed of PEG using a
hydrogel synthesis procedure. Future studies could analyze the use of chitosan-PEG use
with the Park templating method.
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4.2
4.2.1

Evaluation of Microparticles

Validation of FITC–SILY Attachment to Microparticle Surface

The hypothesis of this validation experiment was that FITC-SILY would attach to
the surface of the microparticles through a reaction with the maleimide and the cysteine
in the SILY. The results of the validation of FITC-SILY attachment show microparticles
with a distinct fluorescent FITC-SILY shell around a non-florescent core. The nonflorescent core represents the non-reactive PLA and PLGA. The FITC-SILY florescent
shell indicates that the SILY is reacting with the free maleimides present on the surface
of the microparticles. Figure 3.3 does show minimal fluorescence on the negative control
microparticles, however compared to the experimental microparticles there is
significantly more fluorescence. This minimal fluorescence seen can be attributed to
some non-specific interactions. The confirmed peptide binding capabilities show that this
microparticle system has the potential to be a platform for attachment of any peptide
containing a free thiol or amine.

4.2.2

Quantification of FITC-SILY Attachment to Microparticles

The hypothesis of this quantification experiment was that there would be a
statically higher concentration of attached FITC-SILY for the experimental
microparticles (Mal-PEG-PLGA) in comparison to the negative control particles
(Methyl-PEG-PLGA). The FITC-SILY concentration of 2mg/mL that was used in the
Validation of Functionalizable Surface Maleimide experiment was shown to
incompletely dissolve in PBS leaving free unattached dye that then contaminated the
samples, specifically the negative control microparticles. So this experiment analyzed the
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optimal FITC-SILY concentration and preparation method for attachment and
quantification. Different concentrations of FITC-SILY were prepared at concentrations
between 0.0625 and 0.0078 mg/mL because these concentrations left the least amount of
undissolved FITC-SILY. The undissolved FITC-SILY can be attributed to insufficient
mixing or a high concentration of FITC-SILY. Various chemicals can be used to enhance
dissolving of the FITC-SILY.
Both, a 1% bovine serum albumin (BSA) and 0.02% Tween 20 were
independently used to block non-specific interactions between the FITC-SILY and the
negative control microparticles. Also in attempt to reduce the hydrophobic interaction
between the PLGA and the FITC, the molecular weight of the PLGA was reduced while
increasing the molecular weight of the PEG. So, a methyl-PEG-PLGA with a molecular
weight of 5,000:4,000 Da was purchased from Akina Inc and used to form the polymer
shell of the negative control microparticles. However, the results of these experiments
were not statistically different but brought this research one step closer to quantifying the
attachment of the FITC-SILY.
The most significant problem was that undissolved FITC-SILY was still present in
the samples. In order to address this issue, Tris(2-carboxyethyl)phosphine hydrochloride
(TCEP-HCl) was added to the FITC-SILY solution to increase the solubility in PBS and
the excess undissolved dye was removed with centrifugation prior to reaction with the
microparticles. This experiment produced significantly different FITC-SILY
concentrations between the experimental and negative control microparticles. A
concentration of 0.0156mg/mL FITC-SILY with TCEP was determined to be the ideal
method for the synthesis of microparticles for quantifying the FITC-SILY. The validation
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of FITC-SILY attachment experiment further confirmed the successful attachment of
FITC-SILY to the maleimides present on the surface of the microparticles.

4.2.3

Validation of Microparticles’ Collagen Binding Capabilities

The hypothesis of the validation of collagen binding experiment was that the
SILY-MAL-PEG-PLGA microparticles would have significantly greater binding to type I
collagen compared to the negative control (Me-PEG-PLGA) microparticles. The SILY
was prepared at the ideal concentration of 0.0156mg/mL which was determined during
the quantification experiments. The amount of microparticles bound to the type I collagen
plate was significantly greater than the negative control microparticles. These results
show that this microparticle system has significant clinical application in that it can bind
specifically to type I collagen and potentially target atherosclerotic regions of blood
vessels.
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4.3

Microparticle Degradation Observations

Upon synthesis of initial microparticles, rapid degradation of the microparticles
was observed. These initial microparticles contained the layers of PEG and PLGA
without the conjugation of the collagen-binding peptide. The degradation of these
particles was attributed to the presence of PEG on the surface of the microparticles and
the inefficient packing of molecules within the microparticle. PEG is known to degrade at
elevated temperature in the presence of oxygen and water through oxidation [6]. The
solution for this problem was the incorporation of a dense core. For this reason, PLA was
the chosen polymer based on biocompatibility and common use in drug delivery systems.
The PLA forms a dense core by adding uniformity and tight packing to the core. Through
the synthesis process, a 20% w/v PLA was the highest concentration of polymer that did
not form a scum layer. A scum layer is produced when a polymer layer forms on top of
the PVA template and adjoins all the microparticles together. This is highly undesirable
and is prevented by ensuring that the polymer is evenly spread before the solvent
evaporates. To further prevent degradation, a 5% w/v PLGA-PEG-Mal was chosen as the
lowest concentration to provide polymer to each well with minimizing the
disorganization of polymers which causes rapid degradation.
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4.4

Conclusions and Future Research

The designed microparticle drug delivery system has the potential to target any
type I collagen in the body, specifically atherosclerotic vessels. Further research should be
conducted to synthesis 5µm microparticles using the currently available PDMS template by
Akina, Inc. This size particle would allow for clearance of the venous system without
occlusion [7]. Also, continued research should be performed with in-vitro testing to validate
the biocompatibility and cytotoxicity of the microparticles with targeted cells. In-vivo testing
should also be performed to analyze the biodistribution of the microparticles within the body.
However, the expected biodistribution results should show targeting to type I collagen after
the reduction of the particles’ size to 5µm.

Impurities present in Figures 3.2-3.3 are shown among the microparticles. These
impurities may be present due to excess PVA that was not properly dissolved and
removed. Future studies should be performed to optimize the procedure in order to
prevent these impurities potentially by increasing the time or temperature during PVA
dissolving.
Further research should be concluded to encapsulate drug within the PLGA core.
Ideal drugs for this drug delivery system are drugs that require targeting to particular tissues
or dugs with low solubility and low oral bioavailability. Hydrophobic drugs are known for
their poor solubility in water. These drugs can be categorized as follows [8]:


Slightly soluble: 1-10mg/mL



Very slightly soluble: 0.1-1mg/mL



Practically insoluble: <0.1mg/mL
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Examples of PLGA based microparticles that have entered the market include:
octreotide acetate, leuprolide acetate, triptorelin acetate, triptorelin pamoate, triptorelin, ect.
[9]. Park et al. used the templating method to incorporate the hydrophobic drugs: felodipine,
risperidone, progesterone, and paclitaxel [3]. Many different researchers have incorporated
hydrophobic drugs into PLGA cores, but studies have also determined methods to
incorporate hydrophilic drugs within the core. Gaignaux et al encapsulated anti-inflammatory
and hydrophilic drug, Clonidine, into PLGA microparticles with the use of large aqueous
phases to form the second water-in-oil-in-water (w/o/w) emulsion [10]. Further research
including: scaling down the size of the microparticles, purifying the synthesized
microparticles, and incorporating drug in the microparticle core will increase the clinical
impact of this microparticle system.
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